Evidence map›Paper›PMID 35759737›Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2022

[Comment on article "Enoxaparin dose associated with decreased risk of death in COVID-19"].

Mateo Porres-Aguilar, Javier E Anaya-Ayala

Open access · greenAbstract readLetter
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Mateo Porres-AguilarTexas Tech University Health Sciences Center and Paul L. Foster School of Medicine, Divisions of Hospital and Adult Thrombosis Medicine, Department of Internal Medicine. El Paso, Texas, United States of America.ORCID 0000-0002-2180-3000
Javier E Anaya-AyalaInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Sección de Cirugía Vascular y Terapia Endovascular, Departamento de Cirugía. Ciudad de México, México.ORCID 0000-0003-0936-3310
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXTexas Tech University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this letter to the editor, apropos of the article "Enoxaparin dose associated with decreased risk of death in COVID-19", it is discussed the role of the current thromboprophylactic strategies, as well as the potential role of heparins in the management of COVID-19.

Indexed as

COVID-19EnoxaparinAnticoagulantsHumansAnticoagulantsEnoxaparinAnticoagulantsHeparinsSARS-CoV-2Venous Thromboembolism

Identifiers

PMID35759737
PMCPMC10396058
OpenAlexW4283712561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.